LadRx Corporation (0I5R.L)
| Previous close | 0.0951 |
| Open | 0.0000 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | N/A |
| Market cap | 20,103 |
| Beta (5Y monthly) | 2.19 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3550 |
| Earnings date | 21 Mar 2023 - 27 Mar 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
LadRx Corporation Issues Corporate Update for 3Q22
LOS ANGELES, November 17, 2022--LadRx Corporation (OTCQB: LADX) ("LadRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today issued the below update to stockholders.
- Business Wire
LadRx Corporation Announces OTCQB Ticker Change to LADX
LOS ANGELES, October 05, 2022--LadRx Corporation (OTCQB: LADX) ("LadRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it is changing its OTCQB ticker symbol from CYTR to LADX effective Thursday, October 6, 2022.
- Business Wire
CytRx Corporation Relaunches as LadRx Corporation
LOS ANGELES, September 23, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, announces that it is relaunching as LadRx Corporation.
